Skip to Content
Merck
  • Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy.

Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy.

Glia (2017-10-27)
Jason R Plemel, Nathan J Michaels, Nina Weishaupt, Andrew V Caprariello, Michael B Keough, James A Rogers, Aran Yukseloglu, Jaehyun Lim, Vikas V Patel, Khalil S Rawji, Samuel K Jensen, Wulin Teo, Belinda Heyne, Shawn N Whitehead, Peter K Stys, V Wee Yong
ABSTRACT

For decades lysophosphatidylcholine (LPC, lysolecithin) has been used to induce demyelination, without a clear understanding of its mechanisms. LPC is an endogenous lysophospholipid so it may cause demyelination in certain diseases. We investigated whether known receptor systems, inflammation or nonspecific lipid disruption mediates LPC-demyelination in mice. We found that LPC nonspecifically disrupted myelin lipids. LPC integrated into cellular membranes and rapidly induced cell membrane permeability; in mice, LPC injury was phenocopied by other lipid disrupting agents. Interestingly, following its injection into white matter, LPC was cleared within 24 hr but by five days there was an elevation of endogenous LPC that was not associated with damage. This elevation of LPC in the absence of injury raises the possibility that the brain has mechanisms to buffer LPC. In support, LPC injury in culture was significantly ameliorated by albumin buffering. These results shed light on the mechanisms of LPC injury and homeostasis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-α-Lysophosphatidylcholine from bovine brain, ≥99%, Type V
Sigma-Aldrich
Calcein, Used for the fluorometric determination of calcium and EDTA titration of calcium in the presence of magnesium.
Sigma-Aldrich
Anti-Olig-2 Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anti-Olig2 Antibody, clone 211F1.1, clone 211F1.1, from mouse
Sigma-Aldrich
1,2-Dilinoleoyl-3-palmitoyl-rac-glycerol, ≥95% (TLC), liquid